Navigation Links
Targeting leukemia cell's gene 'addiction' presents new strategy for treatment
Date:3/3/2010

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

The team, led by Dr Veronika Sexl from the University of Vienna, carried out their research on acute lymphoid leukaemia (ALL) and chronic myelogenous leukaemia (CML), which can both be caused by fusion protein, Bcr-Abl, created through the joining of two or more genes originally coded for separate proteins.

This joining of genes results in a complex tumor supporting 'network' which supports the growth and survival of the leukaemic cells. Inhibitor drugs such as 'Imatinib' can block vital signals and lead to leukemia cell death, but there are several mutations which can resist these inhibitors, making them ineffective.

As an alternative strategy the team investigated transcription factors Stat3 and Stat5 which are linked to bcr/abl-induced transformation. The team tested whether Stat3 and Stat5, acting downstream of Bcr-Abl are critical for leukaemia maintenance and if they could be a alternative target for treatment.

"We developed a tumour-specific gene-deletion approach to analyse the roles of Stat5 and Stat3 in Bcr/Abl-induced leukaemia growth," said Sexl. "We discovered that both factors are required for the development of Bcr-Abl, but once established only Stat5 is crucial for the survival and growth of leukemic Cells."

Even mutated forms of bcr-abl, Leukaemia cells, which are resistant to inhibiting drugs such as Imatinib, are still dependent on Stat5.

"Cancer cells undergo extensive adaptations in their signalling and metabolic pathways, thereby becoming dependent on certain genes," said Sexl. "In fact the activity of these genes can become limiting for a cancer cell."

The term 'Non-oncogene addication' (NOA) has been coined to describe this phenomenon of gene dependency and inhibiting these critical genes within the signalling network is predicted to cause system failure and halt the growth of leukaemia cells.

"In this study we demonstrated that bcr-abl, Leukaemia cells are addicted to Stat5 to maintain the leukameic state, concluded Sexl. "We've identified Stat5 as an Achilles' heel in the signalling network downstream of Bcr-Abl. Thus, inhibition of Stat5 may provide a novel therapeutic approach for treatment of leukaemia."


'/>"/>

Contact: Ben Norman
Lifesciencenews@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
2. Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks Data
3. Targeting cancerous vessels
4. Targeting brain cancer cell metabolism may provide new treatment
5. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
6. First live targeting of tumors with RNA-based technology
7. Wistar researchers show targeting normal cells in tumors slows growth
8. Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy's Video-Based Situational Assessments
9. DNA test could be key to targeting treatments for head and neck cancer
10. Another Report Finds Swine Flu Targeting the Young
11. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology: